Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.

NCT00029822 Phase 3 COMPLETED

A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. * Free study-related medical care provided.

Details

Lead sponsor	Sanofi
Phase	Phase 3
Status	COMPLETED
Enrolment	1522
Start date	2001-05
Completion	2005-03

Conditions

• Urinary Retention
• Prostatic Hyperplasia
• Benign Prostatic Hypertrophy

Interventions

• Alfuzosin (SL770499)

Primary outcomes

• occurrence of first episode of acute urinary retention (AUR)

Countries

United States, Australia, Bulgaria, Canada, Denmark, Finland, Greece, Hungary, Israel, Netherlands, Norway, Poland, Portugal, Romania, South Africa, Spain, Sweden